RxDoctor Payments Data

Gary Nash, MD

Cardiovascular Disease · Little Rock, ARNPI 1326274952

Payments from drug & device makers

$1,457in general payments, 2019–2025

Across 31 payments — averaging $46.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$469
  • Shockwave Medical, Inc$363
  • Boston Scientific$231
  • Johnson & Johnson$90
  • Penumbra, Inc.$66
  • Novartis$65
  • plus $173 from 7 others

What the payments were for

  • Food & beverage$1,41197%
  • Education$463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,457 in reported general payments places this provider in the 30th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$436,988
Medicare patients
1,602
Services billed
6,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban756$643,746
EntrestoSacubitril/Valsartan215$216,244
XareltoRivaroxaban173$126,376
MultaqDronedarone Hcl72$84,178
FarxigaDapagliflozin Propanediol44$33,497
Repatha SureclickEvolocumab44$31,442
Repatha SyringeEvolocumab44$30,646
JardianceEmpagliflozin14$18,622
BrilintaTicagrelor20$12,542
Metoprolol Succinate885$9,785
Atorvastatin Calcium1,185$8,680
Potassium Chloride480$7,481
Losartan Potassium903$6,496
Clonidine23$4,519
ClopidogrelClopidogrel Bisulfate560$4,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$643,746756 claims
NovartisEntresto$65$216,244215 claims
Johnson & JohnsonXarelto$90$126,376173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →